Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry
- 24 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (7) , 1013-1022
Abstract
Aims: In recent years, stroke prevention in patients with atrial fibrillation (AF) has radically changed, with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis are needed. Methods and results: We report 1-year follow-up data from the EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes were assessed according to antithrombotic therapy. At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with NOACs only; and 1163 (12.0%) with antiplatelet and oral anticoagulant. At 1-year follow-up, there was a low rate of stroke (0.7%) and any thromboembolic event (TE) (1.2%), while haemorrhagic events occurred in 222 patients (2.3%). Cardiovascular (CV) death and all-cause death occurred in 3.9% and 5.2% of patients, respectively. Cumulative survival for all the three main outcomes considered was highest amongst patients treated only with NOACs (P < 0.0001). Multivariable-adjusted Cox regression analysis found that VKA or NOACs use was independently associated with a lower risk for any TE/acute coronary syndrome/CV death, while all treatments were independently associated with a lower risk for CV death and all-cause death. Conclusion: The 1-year follow-up of EORP-AF General Long-Term Registry reported a low occurrence of thromboembolic and haemorrhagic events, although mortality was high. Both VKA and NOACs were associated with a lower risk of all main adverse outcomes. All treatments were associated with a lower risk for CV death and all-cause death.Keywords
Funding Information
- Abbott Vascular Int.
- Amgen Cardiovascular
- AstraZeneca
- Bayer AG
- Boehringer Ingelheim
- Boston Scientific
- The Bristol Myers Squibb and Pfizer Alliance
- Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
- Gedeon Richter Plc.
- Menarini Int. Op.
- Novartis Pharma AG
- Sanofi
- Servier
- Atrial Fibrillation Network
- AFNET
This publication has 21 references indexed in Scilit:
- Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patientsThrombosis and Haemostasis, 2017
- Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial FibrillationJACC, 2017
- Causes of Death in Anticoagulated Patients With Atrial FibrillationJACC, 2016
- Causes of Death and Influencing Factors in Patients with Atrial FibrillationThe American Journal of Medicine, 2016
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace, 2016
- Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFJournal of the American Heart Association, 2016
- Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trialClinical Research in Cardiology, 2015
- Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)European Heart Journal, 2014
- A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General RegistryEP Europace, 2013
- Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AFAmerican Heart Journal, 2011